Skip to main content
Top
Published in: Rheumatology and Therapy 1/2024

Open Access 13-11-2023 | Sarilumab | Correction

Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry

Authors: Jeffrey R. Curtis, Huifeng Yun, Lang Chen, Stephanie S. Ford, Hubert van Hoogstraten, Stefano Fiore, Kerri Ford, Amy Praestgaard, Markus Rehberg, Ernest Choy

Published in: Rheumatology and Therapy | Issue 1/2024

Login to get access

Excerpt

Correction: Rheumatol Ther (2023) 10:1055–1072 https://doi.org/10.1007/s40744-023-00568-8
Appendix
Available only for authorised users
Metadata
Title
Correction: Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry
Authors
Jeffrey R. Curtis
Huifeng Yun
Lang Chen
Stephanie S. Ford
Hubert van Hoogstraten
Stefano Fiore
Kerri Ford
Amy Praestgaard
Markus Rehberg
Ernest Choy
Publication date
13-11-2023
Publisher
Springer Healthcare
Published in
Rheumatology and Therapy / Issue 1/2024
Print ISSN: 2198-6576
Electronic ISSN: 2198-6584
DOI
https://doi.org/10.1007/s40744-023-00607-4

Other articles of this Issue 1/2024

Rheumatology and Therapy 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine